Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Confluent (NASDAQ: CFLT) reported second quarter EPS of $0.09, better than the analyst estimate of $0.08. Revenue for the quarter came in at $270.8M versus the consensus estimate of $278.29M.
Guidance
Confluent sees Q3 2025 EPS of $0.09-$0.10 versus the analyst consensus of $0.09.
Confluent sees Q3 2025 revenue of $281.00M-$282.00M versus the analyst consensus of $292.50M.
Confluent sees FY 2025 revenue of $1.10B-$1.11B versus the analyst consensus of $1.15B.
Confluent’s stock price closed at $26.38. It is up 33.10% in the last 3 months and up 5.44% in the last 12 months.
Confluent saw 17 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Confluent’s stock price’s past reactions to earnings here.
According to InvestingPro, Confluent’s Financial Health score is "fair performance".
Check out Confluent’s recent earnings performance, and Confluent’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar